C12N 2310/342
Hemimers, i.e. of the type ====----
C12N2310/342 (Hemimers, i.e. of the type ====----) appears on 18 US grants and 26 published applications in this corpus.
Search patents in C12N- Granted patents
- 18
- Published applications
- 26
- Assignees
- 6
- Inventors
- 24
- Latest grant
- 20 Sep 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 3 |
| 2011 | 0 | 2 |
| 2012 | 0 | 0 |
| 2013 | 3 | 1 |
| 2014 | 0 | 2 |
| 2015 | 2 | 2 |
| 2016 | 0 | 3 |
| 2017 | 3 | 0 |
| 2018 | 4 | 6 |
| 2019 | 1 | 0 |
| 2020 | 2 | 3 |
| 2021 | 0 | 0 |
| 2022 | 2 | 2 |
By publication year.
Recent patents
- Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA20 Sep 2022US 11,447,777 B2Dicerna Pharmaceuticals, Inc.
- Organic compositions to treat EPAS1-related diseases1 Mar 2022US 11,261,444 B2Arrowhead Pharmaceuticals, Inc.
- Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA25 Aug 2020US 10,752,899 B2Dicerna Pharmaceuticals, Inc.
- Organic compositions to treat EPAS1-related diseases21 Jan 2020US 10,538,765 B2Arrowhead Pharmaceuticals, Inc.
- 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations19 Nov 2019US 10,478,449 B2Ionis Pharmaceuticals, Inc.
- 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations15 Sep 2022US 2022/0288100 A1Ionis Pharmaceuticals, Inc.
- Antisense oligonucleotides for allele specificity10 Mar 2022US 2022/0073932 A1ARNAY Sciences LLC
- Methods and compositions for the specific inhibition of kras by asymmetric double-stranded rna8 Oct 2020US 2020/0318118 A1Dicerna Pharmaceuticals, Inc.
- 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations3 Sep 2020US 2020/0276222 A1Ionis Pharmaceuticals, Inc.
- Organic compositions to treat epas1-related diseases18 Jun 2020US 2020/0190517 A1Arrowhead Pharmaceuticals, Inc.
Most cited
By later US patents
- Extended dicer substrate agents and methods for the specific inhibition of gene expression113US 8,513,207 B2Dicerna Pharmaceuticals, Inc. · 2013
- Chimeric oligomeric compounds and their use in gene modulation25US 9,096,636 B2Isis Pharmaceuticals, Inc. · 2015
- Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA9US 8,372,816 B2Dicerna Pharmaceuticals, Inc. · 2013
- Extended dicer substrate agents and methods for the specific inhibition of gene expression4US 10,131,912 B2Dicerna Pharmaceuticals, Inc. · 2018
- 2′-methoxy substituted oligomeric compounds and compositions for use in gene modulations4US 9,827,263 B2Ionis Pharmaceuticals, Inc. · 2017